2Lygidakis NJ, Kosmidis P, Ziras N, et al. Combined transarterial targeting locoregional immunotherapy-chemotherapy for patients with unresectable hepatocellular carcinoma: a new alternative for an old problem[J]. J lnterferon Cytokine Res, 1995, 15:467 - 472.
3Dinney CP, Bielenberg DR, Perrotte P, et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration[ J]. Cancer Res, 1998, 58:808 - 814.
4Balasubramaniyan V, Shukla R, Murugaiyan G, et al. Mouse recombinant leptin protects human hepatoma HepG2 against apoptosis, TNF-alpha response and oxidative stress induced by the hepatotoxin - ethanol[ J]. Biochim biophys Acta, 2007, 1770 : 1136 - 1144.
5Chan RC, Xie H, Zhao GP, et al. Dendritomas formed by fusion of mature dendritic cells with allogenic human hepatocellular carcinoma cells activate autologous cytotoxic T lymphocytes[ J]. Immunol Lett, 2002, 83 :101 - 109.
6Kountouras J, Boura P, Kouklakis G. Locoregional immunochemotherapy in hepatocellular carcinoma [ J ]. Hepatogastroenterology, 2002, 49:1109 -1112.
7Haruta I, Yamauchi K, Aruga A, et al. Analytical study of the clinical response to two distinct adoptive immunotherapies for advanced hepatocellular carcinoma: comparison between LAK cell and CTL therapy [ J ]. J lmmunother Emphasis Tumor lmmunol, 1996, 19:218 - 223.
8Schimitz V, Barajas M, Wang L, et al. Adenovirus mediated CD40 ligand gene therapy in a rat model of rothotopic htaptocellular carcinoma[J]. Hepatology, 2001, 34:72 -81.
